Time Is Ripe For Global Action On Orphan Biosimilars
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.
You may also be interested in...
Developing biosimilar orphan drugs is fraught with challenges and needs buy-in from regulators, developers, patients and clinicians.
Immunotherapies for esophageal cancer from BMS and MSD are among the medicines that Scotland’s health technology appraisal body has recommended for use on the National Health system.
Indication-based pricing and tackling complications caused by competition law could help the UK catch up with other countries when it comes to market access for combination therapies.